27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Deciphera Pharmaceuticals Inc (NASDAQ:DCPH)’s kinase switch control platform has largely gone unnoticed on the Street.
The nascent portfolio caught an analyst's attention this week.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The Rating
B Riley analyst Madhu Kumar initiated coverage on Deciphera with a Buy rating and $43 price target.
The Thesis
The analyst expects Deciphera’s DCC-2618 to post positive Phase 3 results in fourth-line gastrointestinal stromal tumors in 2019 and to start Phase 3 studies for second-line GIST in the latter half of 2018.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
Phase 1 studies for the fourth-line indication demonstrated efficacy in disease control rate and early progression-free survival data. Early results in the second-line indication lend additional confidence in success against Pfizer Inc. (NYSE:PFE)’s Sutent.
“Consequently, the second-line opportunity for DCC-2618 could provide a critical edge in the GIST market, particularly in relation to competing c-Kit/PDGFRα TKI avapritinib from Blueprint Medicines Corp (NASDAQ:BPMC), for which Phase 3 studies in third-line GIST, versus Stivarga from Bayer, are guided to start in the first half of 2018,” Kumar said in a Thursday note.
“Taken as a whole, we see a broader opportunity for DCC-2618 in GIST in the second-line setting.”
Price Action
At the time of publication, Deciphera shares were up 0.8 percent at $28.93.
Related Links:
Argus Downgrades Biogen On Trial Delays, Competition In MS, Alzheimer's Drugs
Morgan Stanley Targets New All-Time High For Bristol-Myers, Upgrades To Overweight
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.